Compare TY & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | PVLA |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | TY | PVLA |
|---|---|---|
| Price | $35.64 | $158.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $171.87 |
| AVG Volume (30 Days) | 24.7K | ★ 182.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104,350.18 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.53 | $40.92 |
| 52 Week High | $36.05 | $161.38 |
| Indicator | TY | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Tri-Continental Corp is a closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.